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INTRODUCTION
Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, distinction should be made between «nice to know» and «need to know» pharmacogenomic data, as many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.
PERSONALIZED PRESCRIPTION
Personalized prescription can be expressed as personalizing dosing and/or drug selection and should include genetic as well as environmental (e.g. co-medications, herbal medicines, smoking, foods, beverages) and personal (e.g. age, gender, ethnicity, illnesses) variables (1) .
PHARMACOKINETIC PATHWAY-RELATED GENES FOR PERSONALIZED DOSING
Among genes involved in pharmacokinetics, the members of the cytochrome P450 (CYP) family display large interindividual and interethnic variability in activity. Thus, the FDA EMs, with a 10-fold higher mean plasma concentration measured in the former group.
Although having no impact on discontinuation due to adverse drug reactions (ADRs), higher prevalence of several ADRs (e.g., decreased appetite, insomnia, sedation, tremor or itching)
were noted in PMs with, for example, a 3-fold difference in depression prevalence between PMs and EMs (6% and 2%, respectively). Despite recommendations for dose-adjustment in CYP2D6 PMs or with co-prescription of potent CYP2D6 inhibitors, the drug label does not require CYP2D6 genotyping; new studies are needed to establish whether CYP2D6 UMs need higher than maximal recommended doses.
CYP2B6 is also highly polymorphic but under strong regulation by ligand-activated nuclear receptors, in contrast to CYP2D6, and may be involved in the metabolism of more drugs than initially thought. Methadone, an opioid agonist used for maintenance treatment in opioid addiction, can prolong the QT interval with risk for ventricular tachyarrythmia and Torsades de Pointes. Methadone is a chiral mixture of (R)-methadone, the major agonist on opioid receptors, and (S)-methadone, a weak agonist but more potent blocker of the cardiac hERG channel responsible for QT interval prolongation. Methadone is mainly metabolized by CYP2B6 and CYP3A4, while (S)-methadone is metabolized preferentially by CYP2B6.
Compared to CYP2B6 EMs, slow metabolizers had longer QTc intervals (odds ratio, OR=6.3;
p=0.003) during methadone treatment (2) . CYP2B6 genotyping cannot substitute for the electrocardiogram to predict cardiac arrhythmias and sudden death in methadone patients since diminished CYP2B6 activity is associated with a large number of CYP2B6 SNPs and haplotypes (several of them with yet unknown functions), and since pharmacodynamic related-pathway genes in the heart and other factors (e.g. electrolyte disturbances) may be important, too.
CYP1A2 is involved in particular in the metabolism of clozapine, an atypical antipsychotic.
Clozapine appears to be a more promising drug for personalizing dosing since TDM reviews have definitively established that efficacy is associated with plasma clozapine concentration > 350 ng/ml (3). Rare cases of genetic CYP1A2 variants have been associated with very low or high clozapine metabolic activity but currently CYP1A2 genotyping is not informative in most patients. Studies have also shown that CYP1A2 activity is also controlled by other (non CYP1A2) genetic factors, including the P450 oxydo-reductase and the nuclear receptor genes. However, genotyping of those additional genes adds little in predicting CYP1A2 variability, possibly due in part to the environmental influence on CYP1A2 activity (for example decreased by inhibitors such as oral contraceptives that may contribute to lower female activity and increased by inducers such as smoking). Thus, phenotyping tests (in vivo measurement of the activity using a probe substance such as caffeine) or TDM are more appropriate for personalized dosing of clozapine or of other CYP1A2-dependent drugs.
The CYP3A subfamily, crucial for the metabolism of approximately half of all marketed drugs, is comprised of CYP3A4, CYP3A5 and CYP3A7, which have overlapping substrate specificities. Inducers and inhibitors have major influence on CYP3A activity and genotyping is not clinically relevant unless the drug is preferentially metabolized by CYP3A5 (to our knowledge there are no example in psychiatry).
In summary, for personalized dosing, genotyping of pharmacokinetic pathway-related genes can be most informative in addition to TDM, particularly at the beginning of the pharmacological treatment, to modify dosing. However, TDM remains essential, as it combines the influence of environmental and personal factors involved in metabolism and transport of drugs and allows the measurement of active metabolites.
PHARMACODYNAMIC PATHWAY-RELATED GENES FOR PERSONALIZED DRUG

SELECTION
Genetic testing of pharmacodynamic factors is presently more promising for preventing rare idiosyncratic ADRs rather than to predict response to treatment. Carbamazepine, an anticonvulsant and a mood-stabilizing drug, can cause the Stevens-Johnson syndrome (SJS)-toxic epidermal necrolysis (TEN). According to the FDA labeling of carbamazepine, these reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian population but the risk is highly increased in patients of Asian ancestry. In this population, the HLA-B*1502 allele has been identified as a predictor of SJS-TEN (OR=1357, p=1.6*10 -41 ). FDA carbamazepine drug labeling requires that Asian ancestry patients should be screened for the presence of HLA-B*1502 prior to initiating treatment.
Patients carrying this allele should not be treated with carbamazepine unless the benefit clearly outweighs the risk. A prospective screening in Taiwan of HLA-B*1502 before carbamazepine prescription in 4877 patients provided the proof of concept. No SJS-TEN case was observed in the HLA-B*1502 negative patients whereas 10 cases were expected based on historical incidence without screening (4) . The HLA-A*3101 allele has been proposed as a clinically relevant marker to predict hypersensitivity reactions to carbamazepine in Caucasians and Japanese, but has low sensitivity. Another variant of HLA (HLA-DQB1) has been associated with clozapine-induced agranulocytosis (OR=16.9, p<0.001) and could be useful to identify patients with an exceptionally high risk, but due to the low test sensitivity, it cannot yet replace white blood cell monitoring (5) . 1.3x0.215) ).
Although the value is similar to carbamazepine, the cost-benefit evaluation for HLA-DQB1
genotyping must take into account that it does not replace the mandatory hematological monitoring which decreases the interest in this test at the current price. Concerning pharmacokinetic pathway-related genes, dose recommendations according to CYP genotypes have been published for several psychotropic drugs. However, due to the very low sensitivity of the tests, very high NNG would be calculated. This can explain, in conjunction with the low specificity of the tests, why genotyping of pharmacokinetic pathway-related genes such as CYP isoforms are presently mostly done in psychiatry on a retrospective basis to understand unusual drug responses.
PERSPECTIVES
The large prospective RCTs needed to establish the classical proof of concept as well as the cost-benefit ratio of pharmacogenomics in psychiatry will not happen due to very high costs and lack of funding mechanism. However, very rapid technological advances and the
